TRIPLE THERAPY WITH RITUXIMAB, INTRAVENOUS IMMUNOGLOBULIN, AND INTRAVITREAL CORTICOSTEROIDS FOR MELANOMA-ASSOCIATED RETINOPATHY: TTRIIC DOES THE TRICK
| Autor: | Saif Hamdan, Mark P. Breazzano, Anthony B. Daniels |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Male
medicine.medical_specialty Visual acuity genetic structures medicine.medical_treatment Nyctalopia Adrenal Cortex Hormones Ophthalmology Electroretinography medicine Humans Melanoma Aged medicine.diagnostic_test Paraneoplastic Syndromes Ocular business.industry Wide local excision Immunoglobulins Intravenous General Medicine medicine.disease eye diseases Regimen Steroids Rituximab Interferons medicine.symptom business medicine.drug Retinopathy |
| Zdroj: | RETINAL Cases & Brief Reports. 16:775-778 |
| ISSN: | 1935-1089 |
| Popis: | Melanoma-associated retinopathy responds poorly to currently-available therapies, with continued chronic decline in visual function being the norm, despite treatment. The purpose of this report is to describe the excellent response of a patient with melanoma-associated retinopathy to a triple therapy regimen of rituximab, intravenous immunoglobulin, and intravitreal corticosteroids.Single interventional case report describing management of melanoma-associated retinopathy and the patient's response to this treatment. Retinal function was monitored by serial visual acuity, fundus exams, Goldmann visual fields, and electroretinography.A 65-year old man presented with new onset photopsia, decrease visual acuity and nyctalopia in both eyes in the setting of recently-diagnosed Stage IIIB melanoma, initially treated with wide local excision and adjuvant interferon. He was diagnosed with melanoma-associated retinopathy that initially worsened during his course of interferon for treatment of the melanoma. We initiated triple therapy with rituximab, intravenous immunoglobulin, and intravitreal corticosteroids, and this resulted in full return of electroretinography function and resumption of 20/20 visual acuity in both eyes.This is the first reported case of the utility of triple therapy with rituximab, intravenous immunoglobulin, and intravitreal steroids for successful management of melanoma-associated retinopathy as demonstrated by improvement in acuity, symptoms, visual fields, and electroretinography. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|